Kennedy Capital Management LLC Purchases 9,964 Shares of BioNTech SE (NASDAQ:BNTX)

Kennedy Capital Management LLC grew its holdings in BioNTech SE (NASDAQ:BNTX) by 258.4% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 13,820 shares of the company’s stock after purchasing an additional 9,964 shares during the quarter. Kennedy Capital Management LLC’s holdings in BioNTech were worth $1,575,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also modified their holdings of BNTX. SG Americas Securities LLC grew its holdings in BioNTech by 412.3% during the 4th quarter. SG Americas Securities LLC now owns 41,470 shares of the company’s stock worth $4,726,000 after acquiring an additional 33,375 shares during the period. Mirabaud & Cie SA bought a new position in shares of BioNTech in the 4th quarter worth $684,000. Bank of New York Mellon Corp increased its holdings in BioNTech by 4.3% in the fourth quarter. Bank of New York Mellon Corp now owns 3,677 shares of the company’s stock valued at $419,000 after purchasing an additional 150 shares during the last quarter. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors acquired a new position in BioNTech in the fourth quarter valued at about $1,118,000. Finally, Retireful LLC acquired a new position in BioNTech in the fourth quarter valued at about $260,000. 15.52% of the stock is owned by institutional investors.

BioNTech Stock Performance

Shares of BNTX stock opened at $102.34 on Tuesday. The firm has a market cap of $24.56 billion, a PE ratio of -48.73 and a beta of 1.07. BioNTech SE has a 12 month low of $76.53 and a 12 month high of $131.49. The company’s fifty day simple moving average is $104.24 and its 200-day simple moving average is $111.51. The company has a quick ratio of 7.21, a current ratio of 7.33 and a debt-to-equity ratio of 0.01.

BioNTech (NASDAQ:BNTX) last issued its quarterly earnings results on Monday, March 10th. The company reported $1.08 EPS for the quarter, topping the consensus estimate of $0.38 by $0.70. The firm had revenue of $1.19 billion for the quarter, compared to analysts’ expectations of $1.24 billion. BioNTech had a negative net margin of 15.16% and a negative return on equity of 2.35%. The company’s revenue for the quarter was down 19.5% on a year-over-year basis. During the same period in the previous year, the firm posted $1.90 EPS. Equities research analysts expect that BioNTech SE will post -3.88 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on the company. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $171.44 price target on shares of BioNTech in a research note on Tuesday, March 11th. Truist Financial assumed coverage on shares of BioNTech in a report on Friday, January 10th. They issued a “buy” rating and a $172.00 target price on the stock. BMO Capital Markets boosted their price target on shares of BioNTech from $130.00 to $143.00 and gave the company an “outperform” rating in a report on Tuesday, March 11th. Citigroup started coverage on BioNTech in a research note on Thursday, March 13th. They set a “buy” rating and a $145.00 price objective on the stock. Finally, HC Wainwright decreased their target price on BioNTech from $150.00 to $145.00 and set a “buy” rating for the company in a research note on Tuesday, April 1st. Three analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, BioNTech presently has a consensus rating of “Moderate Buy” and an average target price of $143.44.

BioNTech Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.